JP2016523846A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523846A5 JP2016523846A5 JP2016517984A JP2016517984A JP2016523846A5 JP 2016523846 A5 JP2016523846 A5 JP 2016523846A5 JP 2016517984 A JP2016517984 A JP 2016517984A JP 2016517984 A JP2016517984 A JP 2016517984A JP 2016523846 A5 JP2016523846 A5 JP 2016523846A5
- Authority
- JP
- Japan
- Prior art keywords
- iron oxide
- dosage form
- solid dosage
- light stabilizer
- titanium dioxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 132
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 122
- 239000002775 capsule Substances 0.000 claims description 105
- 239000004611 light stabiliser Substances 0.000 claims description 70
- 239000004408 titanium dioxide Substances 0.000 claims description 61
- 235000010215 titanium dioxide Nutrition 0.000 claims description 61
- 239000003826 tablet Substances 0.000 claims description 56
- CEZCCHQBSQPRMU-LLIZZRELSA-L Allura red AC Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1\N=N\C1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-LLIZZRELSA-L 0.000 claims description 49
- 239000004191 allura red AC Substances 0.000 claims description 49
- 235000012741 allura red AC Nutrition 0.000 claims description 49
- YOZBGTLTNGAVFU-UHFFFAOYSA-N roxadustat Chemical compound C1=C2C(C)=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C1OC1=CC=CC=C1 YOZBGTLTNGAVFU-UHFFFAOYSA-N 0.000 claims description 44
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 40
- 239000007909 solid dosage form Substances 0.000 claims description 40
- 239000000654 additive Substances 0.000 claims description 33
- 230000000996 additive effect Effects 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 24
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 20
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 20
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 20
- OIQPTROHQCGFEF-QIKYXUGXSA-L Sunset Yellow FCF Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-QIKYXUGXSA-L 0.000 claims description 20
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 20
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 20
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 20
- 229960001021 lactose monohydrate Drugs 0.000 claims description 20
- 235000019359 magnesium stearate Nutrition 0.000 claims description 20
- 229940057948 magnesium stearate Drugs 0.000 claims description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 20
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 20
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 20
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 20
- 229940069328 povidone Drugs 0.000 claims description 20
- 239000004173 sunset yellow FCF Substances 0.000 claims description 20
- 235000012751 sunset yellow FCF Nutrition 0.000 claims description 20
- 108010010803 Gelatin Proteins 0.000 claims description 16
- 229920000159 gelatin Polymers 0.000 claims description 16
- 239000008273 gelatin Substances 0.000 claims description 16
- 235000019322 gelatine Nutrition 0.000 claims description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims description 16
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 15
- 229910052782 aluminium Inorganic materials 0.000 claims description 15
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 claims description 12
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000049 pigment Substances 0.000 claims description 8
- -1 methyl-7-phenoxy-isoquinoline-3-carbonyl Chemical group 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 208000007502 anemia Diseases 0.000 claims description 4
- 235000013980 iron oxide Nutrition 0.000 claims description 4
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 claims description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 4
- 239000001053 orange pigment Substances 0.000 claims description 4
- 238000006303 photolysis reaction Methods 0.000 claims description 4
- 230000015843 photosynthesis, light reaction Effects 0.000 claims description 4
- 239000001054 red pigment Substances 0.000 claims description 4
- 239000001052 yellow pigment Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 239000001055 blue pigment Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000001056 green pigment Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000010936 titanium Substances 0.000 claims 1
- 229910052719 titanium Inorganic materials 0.000 claims 1
- 239000000945 filler Substances 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361831909P | 2013-06-06 | 2013-06-06 | |
| US61/831,909 | 2013-06-06 | ||
| PCT/US2014/041021 WO2014197660A1 (en) | 2013-06-06 | 2014-06-05 | Pharmaceutical formulations of a hif hydroxylase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019104562A Division JP6861758B2 (ja) | 2013-06-06 | 2019-06-04 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523846A JP2016523846A (ja) | 2016-08-12 |
| JP2016523846A5 true JP2016523846A5 (enExample) | 2017-07-13 |
| JP6604941B2 JP6604941B2 (ja) | 2019-11-13 |
Family
ID=51063834
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517984A Active JP6604941B2 (ja) | 2013-06-06 | 2014-06-05 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
| JP2019104562A Active JP6861758B2 (ja) | 2013-06-06 | 2019-06-04 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
| JP2021057424A Withdrawn JP2021100971A (ja) | 2013-06-06 | 2021-03-30 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
| JP2023049709A Pending JP2023068197A (ja) | 2013-06-06 | 2023-03-27 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019104562A Active JP6861758B2 (ja) | 2013-06-06 | 2019-06-04 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
| JP2021057424A Withdrawn JP2021100971A (ja) | 2013-06-06 | 2021-03-30 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
| JP2023049709A Pending JP2023068197A (ja) | 2013-06-06 | 2023-03-27 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20160120859A1 (enExample) |
| EP (2) | EP3003284B1 (enExample) |
| JP (4) | JP6604941B2 (enExample) |
| KR (3) | KR102291860B1 (enExample) |
| CN (5) | CN105377242A (enExample) |
| AU (1) | AU2014274890B2 (enExample) |
| CA (1) | CA2914049C (enExample) |
| CY (1) | CY1122951T1 (enExample) |
| DK (1) | DK3003284T3 (enExample) |
| ES (1) | ES2786924T3 (enExample) |
| HR (1) | HRP20200615T1 (enExample) |
| HU (1) | HUE049623T2 (enExample) |
| IL (3) | IL296484B2 (enExample) |
| LT (1) | LT3003284T (enExample) |
| ME (1) | ME03777B (enExample) |
| MX (3) | MX2015016536A (enExample) |
| PL (1) | PL3003284T3 (enExample) |
| PT (1) | PT3003284T (enExample) |
| RS (1) | RS60464B1 (enExample) |
| SG (1) | SG11201509764RA (enExample) |
| SI (1) | SI3003284T1 (enExample) |
| SM (1) | SMT202000190T1 (enExample) |
| WO (1) | WO2014197660A1 (enExample) |
| ZA (1) | ZA201508712B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145616B (zh) | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| SG11201500234YA (en) | 2012-07-16 | 2015-02-27 | Fibrogen Inc | Process for making isoquinoline compounds |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| EP3470397B1 (en) | 2012-07-16 | 2021-12-29 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| IL296484B2 (en) | 2013-06-06 | 2025-03-01 | Fibrogen Inc | Pharmaceutical formulations of HIF hydroxylase inhibitor |
| NZ735973A (en) | 2015-04-01 | 2023-06-30 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| WO2019042485A1 (en) | 2017-08-30 | 2019-03-07 | Zentiva, K.S. | FORMS IN THE STRONG STATE OF ROXADUSTAT |
| ES2898878T3 (es) | 2017-09-04 | 2022-03-09 | Sandoz Ag | Cocristal de un inhibidor de la prolil·hidroxilasa de HIF disponible por vía oral |
| CN110664814A (zh) * | 2019-10-24 | 2020-01-10 | 上海长海医院 | Fg-4592在制备治疗炎性肠病药物中的用途 |
| CN110934833B (zh) * | 2019-12-17 | 2022-08-19 | 河北长天药业有限公司 | 一种复方氨酚那敏颗粒 |
| EP4121009A4 (en) * | 2020-03-17 | 2024-04-17 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| WO2022192097A1 (en) * | 2021-03-06 | 2022-09-15 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| WO2023140901A1 (en) * | 2022-01-21 | 2023-07-27 | Elanco Us Inc. | Molidustat formulations and methods of use for treatment of anemia in cats |
| CN116832005A (zh) * | 2022-03-23 | 2023-10-03 | 石药集团中奇制药技术（石家庄）有限公司 | 一种罗沙司他胶囊 |
| CN114796280B (zh) * | 2022-06-15 | 2024-06-25 | 河北长天药业有限公司 | 一种复方氨酚那敏颗粒及其制备工艺 |
| EP4321155A1 (en) * | 2022-08-08 | 2024-02-14 | Sanovel Ilac Sanayi Ve Ticaret A.S. | An oral pharmaceutical composition comprising roxadustat |
| WO2025111214A1 (en) | 2023-11-22 | 2025-05-30 | Fibrogen, Inc. | [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds) |
| CN118436652A (zh) * | 2024-04-18 | 2024-08-06 | 南方医科大学顺德医院(佛山市顺德区第一人民医院) | 一种罗沙司他药物制剂及其应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| HU229475B1 (en) | 2001-12-06 | 2014-01-28 | Fibrogen | Methods of increasing endogenous erythropoietin (epo) |
| US8318703B2 (en) * | 2001-12-06 | 2012-11-27 | Fibrogen, Inc. | Methods for improving kidney function |
| DE10209692A1 (de) | 2002-03-06 | 2003-09-18 | Merck Patent Gmbh | Isochinolinderivate |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| JP4805234B2 (ja) * | 2002-12-16 | 2011-11-02 | キッセイ薬品工業株式会社 | 経口固形医薬 |
| US20060018959A1 (en) | 2002-12-16 | 2006-01-26 | Kissei Pharmaceutical Co. Ltd. | Solid drug for oral use |
| CN103145616B (zh) | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| EP1658074B1 (en) | 2003-08-01 | 2012-11-07 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| WO2005087237A1 (ja) * | 2004-03-16 | 2005-09-22 | Asahi Kasei Pharma Corporation | ファスジル含有製剤及びその安定性を改善する方法 |
| US8703795B2 (en) | 2005-03-02 | 2014-04-22 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| CN101849943A (zh) | 2005-06-06 | 2010-10-06 | 菲布罗根公司 | 使用HIFα稳定剂的改进的贫血治疗 |
| AU2006259352A1 (en) | 2005-06-15 | 2006-12-28 | Fibrogen, Inc. | Use of HIF 1alfa modulators for treatment of cancer |
| UA97349C2 (uk) | 2005-09-08 | 2012-02-10 | Х. Луннбэк А/С | Стійкі тверді склади сертиндолу |
| EP1944029B1 (en) | 2005-10-31 | 2011-12-21 | Kowa Company, Ltd. | Pharmaceutical preparation having excellent photostability |
| GB0523810D0 (en) | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
| CN102351791B (zh) | 2006-01-27 | 2014-10-29 | 菲布罗根有限公司 | 使低氧诱导因子(hif)稳定的氰基异喹啉化合物 |
| JP2009526047A (ja) * | 2006-02-09 | 2009-07-16 | テバ ファーマシューティカル インダストリーズ リミティド | モンテルカストナトリウムの安定な医薬製剤 |
| US20070259960A1 (en) | 2006-02-16 | 2007-11-08 | Fibrogen, Inc. | Compounds and methods for treatment of stroke |
| AU2007234408B2 (en) | 2006-04-04 | 2011-05-19 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as HIF modulators |
| US20100172984A1 (en) * | 2006-06-06 | 2010-07-08 | Bijay Kumar Padhi | tablet dosage form comprising cetirizine and pseudoephedrine |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| JP5683058B2 (ja) | 2007-04-27 | 2015-03-11 | ニプロ株式会社 | 経口固形製剤及びその製造方法 |
| KR20100099113A (ko) | 2007-10-12 | 2010-09-10 | 아스트라제네카 아베 | 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물 |
| WO2009058403A1 (en) | 2007-11-02 | 2009-05-07 | Fibrogen, Inc. | Methods for reducing blood pressure |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| US20110039885A1 (en) | 2007-12-06 | 2011-02-17 | Fibrogen, Inc. | Methods for increasing endothelial progenitor cells |
| EP2231156A1 (en) | 2007-12-07 | 2010-09-29 | Fibrogen, Inc. | Methods for increasing white blood cells |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| CN102264740B (zh) | 2008-08-20 | 2014-10-15 | 菲布罗根有限公司 | 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途 |
| WO2010024908A1 (en) | 2008-08-26 | 2010-03-04 | Fibrogen, Inc. | Methods for treatment of multiple sclerosis |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| US20100144737A1 (en) | 2008-12-08 | 2010-06-10 | Fibrogen, Inc. | Methods for inhibiting t helper cell differentiation |
| WO2010087462A1 (ja) | 2009-01-29 | 2010-08-05 | 大日本住友製薬株式会社 | 内核を有する口腔内崩壊錠 |
| JP2010248106A (ja) * | 2009-04-14 | 2010-11-04 | Dainippon Sumitomo Pharma Co Ltd | フィルムコーティング錠 |
| JP2012176899A (ja) * | 2009-05-19 | 2012-09-13 | Mitsubishi Tanabe Pharma Corp | ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液 |
| WO2012097329A1 (en) | 2011-01-13 | 2012-07-19 | Fibrogen, Inc. | Methods for increasing mean corpuscular volume |
| CN103429239A (zh) | 2011-01-13 | 2013-12-04 | 菲布罗根有限公司 | 增加网织红细胞血红蛋白含量的方法 |
| EP2670750B1 (en) | 2011-02-02 | 2016-09-14 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor |
| CA2842730C (en) | 2011-07-22 | 2018-08-21 | Beijing Betta Pharmaceuticals Co., Ltd | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| US20140309256A1 (en) | 2011-11-09 | 2014-10-16 | Fibrogen, Inc. | Therapeutic Method |
| WO2013134660A1 (en) | 2012-03-09 | 2013-09-12 | Fibrogen, Inc. | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| EP3470397B1 (en) | 2012-07-16 | 2021-12-29 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| SG11201500234YA (en) | 2012-07-16 | 2015-02-27 | Fibrogen Inc | Process for making isoquinoline compounds |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| SG10202009266PA (en) | 2013-01-24 | 2020-10-29 | Fibrogen Inc | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
| IL296484B2 (en) | 2013-06-06 | 2025-03-01 | Fibrogen Inc | Pharmaceutical formulations of HIF hydroxylase inhibitor |
-
2014
- 2014-06-05 IL IL296484A patent/IL296484B2/en unknown
- 2014-06-05 SG SG11201509764RA patent/SG11201509764RA/en unknown
- 2014-06-05 ES ES14735770T patent/ES2786924T3/es active Active
- 2014-06-05 SI SI201431529T patent/SI3003284T1/sl unknown
- 2014-06-05 CN CN201480031209.2A patent/CN105377242A/zh active Pending
- 2014-06-05 EP EP14735770.1A patent/EP3003284B1/en not_active Revoked
- 2014-06-05 US US14/896,353 patent/US20160120859A1/en not_active Abandoned
- 2014-06-05 RS RS20200417A patent/RS60464B1/sr unknown
- 2014-06-05 MX MX2015016536A patent/MX2015016536A/es active IP Right Grant
- 2014-06-05 AU AU2014274890A patent/AU2014274890B2/en active Active
- 2014-06-05 PT PT147357701T patent/PT3003284T/pt unknown
- 2014-06-05 CN CN202010591483.2A patent/CN111728951A/zh active Pending
- 2014-06-05 DK DK14735770.1T patent/DK3003284T3/da active
- 2014-06-05 JP JP2016517984A patent/JP6604941B2/ja active Active
- 2014-06-05 CN CN201910744577.6A patent/CN110448537A/zh active Pending
- 2014-06-05 ME MEP-2020-79A patent/ME03777B/me unknown
- 2014-06-05 KR KR1020157034392A patent/KR102291860B1/ko active Active
- 2014-06-05 EP EP20156653.6A patent/EP3708154A1/en not_active Withdrawn
- 2014-06-05 SM SM20200190T patent/SMT202000190T1/it unknown
- 2014-06-05 HR HRP20200615TT patent/HRP20200615T1/hr unknown
- 2014-06-05 PL PL14735770T patent/PL3003284T3/pl unknown
- 2014-06-05 KR KR1020227041268A patent/KR20220164069A/ko not_active Ceased
- 2014-06-05 KR KR1020217025795A patent/KR20210104173A/ko not_active Ceased
- 2014-06-05 CN CN202010591484.7A patent/CN111728952A/zh active Pending
- 2014-06-05 LT LTEP14735770.1T patent/LT3003284T/lt unknown
- 2014-06-05 WO PCT/US2014/041021 patent/WO2014197660A1/en not_active Ceased
- 2014-06-05 HU HUE14735770A patent/HUE049623T2/hu unknown
- 2014-06-05 IL IL298998A patent/IL298998B2/en unknown
- 2014-06-05 CN CN202010591474.3A patent/CN111728950A/zh active Pending
- 2014-06-05 CA CA2914049A patent/CA2914049C/en active Active
-
2015
- 2015-11-24 IL IL242759A patent/IL242759B2/en unknown
- 2015-11-26 ZA ZA2015/08712A patent/ZA201508712B/en unknown
- 2015-12-01 MX MX2022011225A patent/MX2022011225A/es unknown
- 2015-12-01 MX MX2020003096A patent/MX2020003096A/es unknown
-
2018
- 2018-07-13 US US16/035,503 patent/US10765672B2/en active Active
-
2019
- 2019-06-04 JP JP2019104562A patent/JP6861758B2/ja active Active
-
2020
- 2020-04-27 CY CY20201100383T patent/CY1122951T1/el unknown
-
2021
- 2021-03-10 US US17/198,013 patent/US20220054474A1/en not_active Abandoned
- 2021-03-30 JP JP2021057424A patent/JP2021100971A/ja not_active Withdrawn
-
2023
- 2023-03-27 JP JP2023049709A patent/JP2023068197A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298998B1 (en) | Pharmaceutical formulations of a hif hydroxylase inhibitor | |
| JP5467870B2 (ja) | 異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態 | |
| JP2019137703A5 (enExample) | ||
| ES2435943T3 (es) | Formulaciones de vildagliptina | |
| JP2011098964A5 (enExample) | ||
| US9770437B2 (en) | Compositions of eltrombopag | |
| CA2858941C (en) | Combination of benazepril hydrochloride and pimobendan | |
| JP7093752B2 (ja) | モンテルカストナトリウム製剤 | |
| JP2015120758A5 (enExample) | ||
| JP2016512493A5 (enExample) | ||
| JP6440294B2 (ja) | テルミサルタン含有フィルムコーティング錠剤 | |
| CN108430462B (zh) | 包括富马酸二甲酯的肠溶包衣口服药物制剂 | |
| EA032671B1 (ru) | Твердая лекарственная форма для перорального применения, содержащая доксиламин и пиридоксин и/или их соли | |
| JP6366547B2 (ja) | 光安定性が向上した、プラミペキソール製剤包装体 | |
| US20160143923A1 (en) | Low dose pharmaceutical composition of doxycycline | |
| JP2021024820A (ja) | 光安定性が向上した、ダサチニブ無水物フィルムコーティング錠剤 | |
| JP2020029447A (ja) | 腸溶性高分子及び抗付着剤を含有する顆粒 | |
| CN104434872A (zh) | 一种稳定的盐酸度洛西汀肠溶胶囊及其制备方法 | |
| JP2015193560A (ja) | 医薬組成物 | |
| AU2017244269A1 (en) | Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate | |
| JP2018172361A (ja) | 光安定性を改善した、デュロキセチンを含有する固形製剤 | |
| EP3407873B1 (en) | Process for preparation of a granulate comprising dimethyl fumarate | |
| JP2020002129A (ja) | 光変色性が改善された、デュロキセチン塩酸塩含有顆粒 | |
| JP2025165551A (ja) | 錠剤、錠剤の製造方法、およびパルボシクリブまたはその薬学的に許容される塩の類縁物質の生成を抑制する方法 | |
| JP2022024813A (ja) | アキシチニブ（ｉｖ型）を有効成分とする医薬錠剤及び包装された医薬錠剤 |